Advanced searches left 3/3

Carcinoma Neoadjuvant - Crossref

Summarized by Plex Scholar
Last Updated: 03 December 2022

* If you want to update the article please login/register

Neoadjuvant chemotherapy reduces blood loss during the resection of pediatric choroid plexus carcinomas

OBJECT Choroid plexus carcinomas are unusual brain tumors that originate from the ventricular choroid plexus. Blood losses in small children are not uncommon, often prompting the neurosurgeon to abort the procedure, often leaving residual tumors. Blood loss appears to have significantly decreased in blood pressure after second-look surgery. Histological examination of specimens obtained at a second visit shows reduced vascularity and fibrotic changes in tumor tissue. During CPC surgery, the authors undertook this review to determine the potentially beneficial effect of neoadjuvant chemotherapy on blood loss. METHODS IN this retrospective cohort review, the demographic, medical, and treatment characteristics of 22 consecutive patients with CPC are reported. Particular attention was paid to the effects of neoadjuvant chemotherapy on the extent of resection and intraoperative blood loss. The extent of blood loss was estimated based on transfusion parameters and perioperative changes in hematocrit, with extent of resection estimated based on perioperative neuroimaging. Ten patients did not receive neoadjuvant chemotherapy, and 12 patients were treated with 2u20135 cycles of ICE chemotherapy in a neoadjuvant manner, according to the neoadjuvant community. The 22 patients in the study underwent a total of 37 tumor resection surgeries. Mean blood loss in the neoadjuvant chemotherapy group was 22% of total estimated blood volume as compared to 96% in patients without preoperative chemotherapy. CONCLUSION With a dramatic positive effect on overall survival, the administration of neoadjuvant chemotherapy reduces intraoperative blood loss and increases the risk of resection in children with CPC.

Source link: https://doi.org/10.3171/2014.12.peds14372


Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Abstract: In 30 percent five-year survival, abstract surgery for locoregionally advanced head and neck squamous cell carcinoma findings in 30 %. 32 HNSCC patients are treated with two doses of immune checkpoint blockade using nivolumab or nivolumab plus a single dose of ipilimumab prior to surgery in IMCISION, a non-randomized phase Ib/IIA trial. Primary endpoints are feasibility to resect no later than week 6 and primary tumor pathological response. In 17/20 phase IIa patients and 29/32 total trial patients, physiotherapy response, defined as the percentage change in primary tumor cell percentage from baseline biopsy to on-treatment resection, is evaluable. Patients after COMBO ICB, both in phase IIa and in the full trial, meet the phase IIa primary endpoint threshold of 10%, which is a significant pathological response in 35% of patients. During a median postsurgical follow-up of 24. 0 months, none of the MPR patients experience recurrent HSNCC.

Source link: https://doi.org/10.1038/s41467-021-26472-9


Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Abstract based on the success of checkpoint blockade in some cancer patients, there is still a great deal to improve outcomes. The results from a phase Ib clinical trial in which 17 patients with locally advanced head and neck cell carcinoma were given a murine anti-human OX40 agonist antibody prior to definitive surgical resection were described here. Both increases in CD4+ and CD8+ T cell proliferation two weeks after the administration of anti-OX40 were shown by Peripheral blood phenotyping results. Patients with evaluable tumor tissue in 25% of patients with evaluable tumor tissue are disease-free, with rises in tumor-antigen reactive, proliferating CD103+ cells in 25% of patients with CD8+ TIL, according to the authors, who are disease-free. These results show that anti-OX40 administered before surgery is safe and can cause activation and proliferation of CD4+ and CD8+ T cells in blood and tumors.

Source link: https://doi.org/10.1038/s41467-021-21383-1


The efficacy of neoadjuvant radiotherapy in patients with signet ring cell carcinoma of the rectum: a retrospective case control study

Introduction: Signet ring cell carcinoma of the rectum is a rare rectal tumor, therefore, only limited information is available on the care of patients with this disorder. Although there are literature reviews on signet ring cell carcinoma to radiation therapy, it is unclear if the RT is safe as the first stage of therapy. Each case of the control group was compared to the study group by the following criteria: the year of diagnosis, the cN, and cN clinical stage, as well as the use of RT or CRT. One patient in each group had pathological complete response, and eight patients in the SRCCR group and four patients in the control group had Dworak tumor regression grade 3u20134 u20134.

Source link: https://doi.org/10.18027/2224-5057-2022-12-3-5-10


Addition of Beetroot Extract to Neoadjuvant Adriamycin Cyclophosphamide Regimen Increased Tumor Cell Apoptosis in Mammary Adenocarcinoma Rats

The aim of this research was to determine the apoptotic benefit of adding beetroot extract to the neoadjuvant Adriamycin Cyclophosphamide regimen by examining the expression of p53 and caspase 3 in tumor tissue from mammary adenocarcinoma rats. In the neoadjuvant AC regimen, beetroot extract was present in much higher serums of p53 and caspase 3 expression in comparison to AC treatment alone. Beetroot extract, Adriamycin, Cyclophosphamide, apoptosis, p53. These results indicated that beetroot extract, apoptosis, which was a synergistic effect with the neoadjuvant AC regimen increases tumor cell apoptosis.

Source link: https://doi.org/10.14499/indonesianjcanchemoprev12iss3pp130-136


Impact of Neoadjuvant Therapy on Postoperative Complications in Patients Undergoing Resection for Rectal Adenocarcinoma

The primarystay of treatment for rectal cancer is surgical resection. It's unclear if preoperative chemotherapy and radiation have an effect on postoperative complications. The aim of this report is to assess the effect of neoadjuvant therapy on postoperative complications in patients undergoing a resection of rectal cancer. A retrospective review of 325 patients who underwent surgical resection for rectal cancer from 1984 to 2001 was published. With 19 percent and 14 percent respectively, there was no significant difference between complication rates for APR and SS. However, the SS group reported that 21% of the patients who received radiation had complications compared to 11 percent in those who did not. neoadjuvant therapy had no effect on the incidence of complications in the APR group. However, the SS group did see a pattern between preoperative chemotherapy and radiation, as well as the complication rate.

Source link: https://doi.org/10.1177/000313480407001203


Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?

Methods: In junction adenocarcinoma treated with neoadjuvant RCT versus CT, all patients with locally advanced GEJ adenocarcinoma were treated with neoadjuvant RCT and long-term outcomes were retrospectively analyzed. Complete pathologic response was more prevalent in RCT patients, with a tendency to improved lymph node surveillance. Patients with locally advanced GEJ adenocarcinoma treated with RCT had more postoperative cardiovascular disease, but there were higher rates of complete pathologic response and a trend toward improved locoregional lymph node control.

Source link: https://doi.org/10.3390/cancers14235856


High vs. low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: an endemic area population-based study

Background information Abstract Background The most effective radiotherapy dose for locally advanced esophageal squamous cell carcinoma in endemic areas treated with neoadjuvant concurrent chemotherapy is uncertain. Methods The Taiwan Cancer Registry identified eligible patients diagnosed between 2010 and 2019 in Taiwanes, China. To strike a balance between observable potential confounders and established potential confounders, we used propensity score weighting. The hazard ratio of death was compared to high dose and low dose radiotherapy in the research.

Source link: https://doi.org/10.1007/s12672-022-00594-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions